Medicament for treating rheumatoid arthritis and preparation method

Abstract

The invention belongs to the technical field of biological medicine, and discloses a medicament for treating rheumatoid arthritis and a preparation method. The medicament for treating rheumatoid arthritis is pterocarya stenoptera general flavone. The preparation method comprises the following steps: smashing 10kg of dried Hubei pterocarya stenoptera bark, performing heating reflux extraction with70 percent ethanol in an amount which is 10 times the volume of the dried Hubei pterocarya stenoptera bark by 3 times, each time for 2 hours, performing filtration and combining filtrates; concentrating the combined filtrate under reduced pressure, loading the concentrated filtrate onto the upper end of a D-101 macro-porous resin column, standing for adsorbing for 1 hour, performing elution with purified water in an amount which is 6 times the volume of the D-101 macro-porous resin column, performing elution with 70 percent ethanol in an amount which is 5 times the volume of the D-101 macro-porous resin column, recovering 70 percent ethanol eluant, concentrating under reduced pressure, and performing vacuum freeze drying to obtain a Hubei pterocarya stenoptera general flavone crude extract. The pterocarya stenoptera extract contains abundant flavonoid compound. The flavonoid compound widely exists in lots of vegetables, fruits and medicinal plants in the natural world, is one of important effective components in the traditional Chinese medicine in China, and has the characteristics of wide physiological activity, and low toxic and side effects.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a medicine for treating rheumatoid arthritis and a preparation method thereof. Background technique [0002] At present, the existing technology commonly used in the industry is as follows: Rheumatoid arthritis (rheumatoidarthritis, RA) is a common clinical autoimmune chronic inflammatory disease characterized by excessive proliferation of synovial tissue, pannus formation and bone erosion . According to research reports, the global prevalence of RA is 0.5% to 1%, of which 0.35% in developing countries, while the prevalence of RA in my country is 0.42%. RA leads to significant limitation of joint activities and even physical disability, loss of work ability, lower quality of life, lower life expectancy, and a huge economic burden on the patients themselves, their families and society. According to the survey, for patients without formal treatment, the two-year d...

AI Technical Summary

Problems solved by technology

[0005] (1) At present, Western medicine treats RA with non-steroidal anti-inflammatory drugs, glucocorticoids, disease-modifying anti-rheumatic drugs and biological agents. Difference

[0006] (2) Due to the high price of biological agents, strong immunogenicity, and short half-life, the proportion of application is not high, and it is difficult to promote the use of them at the grassroots level, especially in economically backward areas.

[0007] The difficulty and significance of solving the above technical problems: There are many difficulties in solving the above problems. The technical difficulties in optimizing the efficacy of drugs and reducing adverse drug reactions are relatively large. The limitations of research and development cause safety problems after large-scale use of drugs. Drug denaturation and inactivation due to substandard storage and transportation conditions, effectiveness and safety problems caused by non-standard clinical use, and immune system diseases caused by immunogenicity all need to be resolved urgently

However, solving the above problems requires huge financial support, which in turn increases the cost of drugs and increases the financial burden on patients

Images